Switzerland, BioMedPartners Closes BioMedInvest II, a CHF106M Venture Capital Fund

BioMedPartners, an European provider of private equity and mezzanine financing, closed BioMedInvest II L.P., its second healthcare venture capital fund, at CHF106m.
BioMedInvest II L.P. invests in private early- to mid-stage companies in Germany, Switzerland and neighbouring European countries.
The fund is backed by both existing and new investors, including the two facilities of the European Investment Fund, ERP-EIF and LfA-EIF.
In addition, Dr. Karl Deres will join BioMedPartners as a new Venture Partner and will support the representation office in Munich.
Dr. Deres is a biochemist with a strong background in the pharmaceutical industry as well as broad operational expertise and experience in the biotech sector.
He worked for more than 15 years for Bayer Schering Pharma and Intervet Schering Plough.
In 2007, Deres founded DPC Pharma Consulting, an advisory company offering services in the pharmaceutical and biotech industry, including interim management in the fields of business & strategic corporate development, clinical & regulatory aspects as well as R&D management.

Join the discussion